SUMMIT THERAPEU/S (NASDAQ:SMMT) issued its quarterly earnings results on Wednesday. The company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.13), Fidelity Earnings reports. The company had revenue of $0.66 million during the quarter, compared to the consensus estimate of $4.44 million. SUMMIT THERAPEU/S had a return on equity of 1.16% and a net margin of 0.37%.

Shares of SMMT stock traded down $0.01 on Thursday, hitting $1.81. 1,405 shares of the company’s stock traded hands, compared to its average volume of 97,198. SUMMIT THERAPEU/S has a one year low of $1.10 and a one year high of $14.29. The firm has a market cap of $25.19 million, a P/E ratio of -2.41 and a beta of 1.50.

A number of brokerages have recently commented on SMMT. Zacks Investment Research lowered shares of SUMMIT THERAPEU/S from a “buy” rating to a “hold” rating in a report on Saturday, February 23rd. ValuEngine lowered shares of SUMMIT THERAPEU/S from a “sell” rating to a “strong sell” rating in a report on Wednesday, January 2nd. Oppenheimer reissued a “hold” rating on shares of SUMMIT THERAPEU/S in a report on Thursday, February 14th. Finally, HC Wainwright reissued a “buy” rating on shares of SUMMIT THERAPEU/S in a report on Tuesday, February 19th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. SUMMIT THERAPEU/S currently has a consensus rating of “Hold” and an average target price of $6.92.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at


Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Featured Article: How accurate is the Rule of 72?


Receive News & Ratings for SUMMIT THERAPEU/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SUMMIT THERAPEU/S and related companies with's FREE daily email newsletter.